Literature DB >> 33330804

Metabolic changes of Japanese schizophrenic patients transferred from hospitalization to outpatients.

Yoriyasu Uju1, Tetsuto Kanzaki2, Yuki Yamasaki2, Tadayuki Kondo1, Hideki Nanasawa1, Yu Takeuchi1, Yuta Yanagisawa1, Shun Kusanishi1, Chieko Nakano1, Tetsuro Enomoto1, Akahito Sako3, Hidekatsu Yanai3, Seisuke Mimori4, Kazuei Igarashi5, Tsuyoshi Takizawa6, Tatsuro Hayakawa1.   

Abstract

It is well known that schizophrenic patients have high incidence of metabolic syndrome and life-style related diseases. There are reports that the rates of these diseases are increased more in outpatients than inpatients, but are also reports that the rates are not different between both patient groups. These differences might be related to the length of hospitalization. Hospitalization of Japanese psychiatric patients is about 300 days, much longer than western countries (below 50 days). Therefore, we investigated lipid and glucose metabolism of schizophrenic patients transferred from hospitalization to outpatients at Kohnodai hospital with a mean of 80 days hospitalization period to clarify metabolic characteristics in Japanese patients. Study participants were 144 schizophrenia inpatients and 109 outpatients at Kohnodai Hospital. These 109 outpatients were followed for approximately 2 years, without changes of administrated drugs, and from 144 inpatients. Data from outpatients were obtained at 6 months, 1 year and 2 years after their discharge. Outpatients 2 years after discharge had significantly higher levels of total cholesterol, triglyceride and non-high density lipoprotein (non-HDL) cholesterol than inpatients, accompanied with an increase of body weight. Serum HDL-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) levels had no significant difference between both groups. These lipids and glucose levels also showed the same tendency in outpatients 0.5 year and 1 year after discharge as those after 2 years. We found that schizophrenic patients in our study appeared to have changes of lipid metabolism 2 years after their discharge, but no significant changes of glucose metabolism, such as FPG and HbA1c. 2020, National Center for Global Health and Medicine.

Entities:  

Keywords:  glucose metabolism; inpatients; lipid metabolism; outpatients; schizophrenia

Year:  2020        PMID: 33330804      PMCID: PMC7731271          DOI: 10.35772/ghm.2020.01008

Source DB:  PubMed          Journal:  Glob Health Med        ISSN: 2434-9186


  23 in total

1.  Mendelian randomization analysis of cholesteryl ester transfer protein and subclinical atherosclerosis: A population-based study.

Authors:  Tim Christen; Stella Trompet; Raymond Noordam; Lisanne L Blauw; Karin B Gast; Patrick C N Rensen; Ko Willems van Dijk; Frits R Rosendaal; Renée de Mutsert; J Wouter Jukema
Journal:  J Clin Lipidol       Date:  2017-11-02       Impact factor: 4.766

Review 2.  Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis.

Authors:  Alex J Mitchell; Davy Vancampfort; Kim Sweers; Ruud van Winkel; Weiping Yu; Marc De Hert
Journal:  Schizophr Bull       Date:  2011-12-29       Impact factor: 9.306

3.  Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).

Authors:  Andrew S Levey; Kai-Uwe Eckardt; Yusuke Tsukamoto; Adeera Levin; Josef Coresh; Jerome Rossert; Dick De Zeeuw; Thomas H Hostetter; Norbert Lameire; Garabed Eknoyan
Journal:  Kidney Int       Date:  2005-06       Impact factor: 10.612

Review 4.  Medical risk in patients with bipolar disorder and schizophrenia.

Authors:  John W Newcomer
Journal:  J Clin Psychiatry       Date:  2006       Impact factor: 4.384

5.  Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis.

Authors:  Carsten Hjorthøj; Anne Emilie Stürup; John J McGrath; Merete Nordentoft
Journal:  Lancet Psychiatry       Date:  2017-02-22       Impact factor: 27.083

6.  Serum lipids in schizophrenia and other functional psychoses: a general population northern Finland 1966 birth cohort survey.

Authors:  K Saari; J Jokelainen; J Veijola; H Koponen; P B Jones; M Savolainen; M-R Järvelin; L Lauren; M Isohanni; S Lindeman
Journal:  Acta Psychiatr Scand       Date:  2004-10       Impact factor: 6.392

7.  The interaction of cholesterol absorption and cholesterol synthesis in man.

Authors:  S M Grundy; E H Ahrens; J Davignon
Journal:  J Lipid Res       Date:  1969-05       Impact factor: 5.922

8.  Increased Silent Brain Infarction Accompanied With High Prevalence of Diabetes and Dyslipidemia in Psychiatric Inpatients: A Cross-Sectional Study.

Authors:  Tetsuto Kanzaki; Yoriyasu Uju; Keisuke Sekine; Yukihiro Ishii; Taro Yoshimi; Reiko Yasui; Asuka Yasukawa; Mamoru Sato; Seiko Okamoto; Tetsuya Hisaoka; Masafumi Miura; Shun Kusanishi; Kanako Murakami; Chieko Nakano; Yasuhiko Mizuta; Seisuke Mimori; Shunichi Mishima; Kazuei Igarashi; Tsuyoshi Takizawa; Tatsuro Hayakawa; Kazumi Tsukada
Journal:  Prim Care Companion CNS Disord       Date:  2015-03-26

9.  Premature deaths among individuals with severe mental illness after discharge from long-term hospitalisation in Japan: a naturalistic observation during a 24-year period.

Authors:  Shinsuke Kondo; Yousuke Kumakura; Akiko Kanehara; Daisuke Nagato; Taro Ueda; Tsuneo Matsuoka; Yukiko Tao; Kiyoto Kasai
Journal:  BJPsych Open       Date:  2017-08-11

Review 10.  Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis.

Authors:  David P J Osborn; Christine A Wright; Gus Levy; Michael B King; Raman Deo; Irwin Nazareth
Journal:  BMC Psychiatry       Date:  2008-09-25       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.